Clinical Scorecard: Migaldendranib May Move the Needle in AMD, DME
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |
| Key Mechanisms | Tyrosine kinase inhibitor (TKI) that blocks vascular endothelial growth factor (VEGF), targeting retinal pigment epithelial (RPE) cells and macrophages in inflammatory lesions. |
| Target Population | Patients with wet AMD and DME previously treated with intravitreal injections. |
| Care Setting | Outpatient, potential for at-home administration. |
Key Highlights
- Migaldendranib is a subcutaneous therapy that reduces injection burden.
- No liver or renal toxicity observed; primarily cleared by the kidneys.
- CST decreased significantly in both AMD and DME patients.
- BCVA improved in both study and fellow eyes.
- Potential to decrease supplemental injection needs.
Guideline-Based Recommendations
Diagnosis
- Assess central subfield thickness (CST) and best-corrected visual acuity (BCVA) before treatment.
Management
- Administer 2 mg of migaldendranib subcutaneously monthly or every other month.
Monitoring & Follow-up
- Monitor CST and BCVA regularly; consider supplemental injections if CST exceeds baseline.
Risks
- Injection site reactions (8.6% incidence), cellulitis, and vitreous hemorrhage.
Patient & Prescribing Data
Patients with chronic wet AMD and DME who have previously received intravitreal injections.
Migaldendranib reduces treatment burden by an average of 80% in the study eye and 74.45% in the fellow eye.
Clinical Best Practices
- Consider migaldendranib as a first-line therapy for patients with high injection burden.
- Educate patients on the potential for at-home administration.
- Regularly assess the need for supplemental injections based on CST and BCVA.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
